Hydrocodone News and Research RSS Feed - Hydrocodone News and Research

Three IU researchers receive $2.1 million to develop computational biology models of liver toxicity

Three IU researchers receive $2.1 million to develop computational biology models of liver toxicity

Three Indiana University professors have received $2.1 million to develop a computational model of acetaminophen-induced liver failure -- the leading cause of liver failure in the United States -- by using advanced microscopic and computational technologies that allow scientists to see into the liver of a living animal. [More]
Pain medicine specialist receives award for new advances in oral fluid testing

Pain medicine specialist receives award for new advances in oral fluid testing

This year's Eastern Pain Society Scientific meeting was held at Mount Sinai Beth Israel Medical Center in New York City in late October and is one of the largest meetings of pain physicians and fellows in the tri-state area. [More]
Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Prescription opioids involved in 67.8% of nationwide ED visits in 2010, find researchers

Researchers from Rhode Island and The Miriam hospitals and the Stanford University School of Medicine have found that prescription opioids, including methadone, were involved in 67.8 percent of (or over 135,971 visits to) nationwide emergency department (ED) visits in 2010, with the highest proportion of opioid overdoses occurring in the South. [More]
Viewpoints: Shop around for health coverage; 'gaming' Obamacare; FDA and painkillers

Viewpoints: Shop around for health coverage; 'gaming' Obamacare; FDA and painkillers

My colleagues Margot Sanger-Katz and Amanda Cox wrote recently that shopping around for the best price can be crucial for people renewing their coverage on the health insurance exchanges this fall. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]
KemPharm to initiate clinical trials in Canada for lead product candidate KP201

KemPharm to initiate clinical trials in Canada for lead product candidate KP201

KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it received a No Objection Letter (NOL) from Health Canada to begin clinical trials in Canada for its lead product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen) [More]
First Edition: August 22, 2014

First Edition: August 22, 2014

Kaiser Health News consumer columnist Michelle Andrews writes: "How much leeway do employers and insurers have in deciding whether they'll cover contraceptives without charge and in determining which methods make the cut? Not much, as it turns out, but that hasn't stopped some from trying. Kaiser Health News readers still write in regularly describing battles they're waging to get the birth control coverage they're entitled to" (Andrews, 8/22). [More]
State highlights: Calif. hospital bid draws scrutiny; hospital house calls

State highlights: Calif. hospital bid draws scrutiny; hospital house calls

Prime Healthcare Services Inc., a hospital chain that has come under fire for billing and patient privacy issues, is facing opposition over its potential acquisition of six California hospitals, including two medical centers in Los Angeles County. On Friday, hospital workers, union representatives and elected officials protested against Prime outside St. Vincent Medical Center near downtown Los Angeles, one of the six hospitals put up for sale this year by the Daughters of Charity Health System (Garland, 8/15). [More]
New lifesaving product aims at reducing death toll from heroin abuse

New lifesaving product aims at reducing death toll from heroin abuse

A new, lifesaving product aimed at reducing the death toll from heroin abuse — developed by a professor at the University of Kentucky College of Pharmacy — is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration. [More]
New tool promises to reduce deaths caused by heroin overdose

New tool promises to reduce deaths caused by heroin overdose

A new, lifesaving product aimed at reducing the death toll from heroin abuse - developed by a professor at the University of Kentucky College of Pharmacy - is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration. [More]
Prescription drug deaths drop in Fla. after crackdown on doctors

Prescription drug deaths drop in Fla. after crackdown on doctors

Deaths involving narcotic painkillers dropped 26 percent over two years in Florida after stricter doctor scrutiny, according to a report from the federal Centers for Disease Control and Prevention. [More]
Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities. [More]
State regulators seek to impose controls on new painkiller

State regulators seek to impose controls on new painkiller

Several outlets look at prescription drug issues, including how to handle Zohydro -- a powerful painkiller approved by the FDA in March, and ethical questions raised by new "smart pills." [More]
Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237). [More]
Purdue Pharma seeks FDA authorization to market once-daily hydrocodone bitartrate tablet

Purdue Pharma seeks FDA authorization to market once-daily hydrocodone bitartrate tablet

Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration seeking authorization to market a once-daily, single-entity hydrocodone bitartrate tablet (HYD). [More]

Braeburn announces new clinical trial for Probuphine based on clear guidance from FDA

Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015. [More]
Children get codeine in U.S. emergency rooms, despite risks: Study

Children get codeine in U.S. emergency rooms, despite risks: Study

Despite its potentially harmful effects in children, codeine continues to be prescribed in U.S. emergency rooms, according to new research from UCSF Benioff Children's Hospital San Francisco. [More]
Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Polls have consistently shown that even though the public opposes Obamacare, people like some of its most significant provisions. That's particularly true of the requirement that insurers ignore preexisting conditions when signing up customers for coverage. [More]
Egalet provides business update, reports full year 2013 financial results

Egalet provides business update, reports full year 2013 financial results

Egalet Corporation ("Egalet") today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company. [More]
Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

In preparation for the new ACO environment, leaders recognized the contribution palliative care can make to health care "value," especially in the care of our sickest (and most expensive) patients ... [More]